Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers
Status:
Completed
Trial end date:
2017-03-17
Target enrollment:
Participant gender:
Summary
Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic
kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics
of a single oral dose of finerenone (1.25 mg tablet and 5 x 0.25 mg tablets) using a novel
orodispersible tablet formulation for the treatment of children, in comparison to the adult
tablet formulation.